Canadian regulators have adopted ICH’s E17 guidelines on multi-regional trials.

The agency said current Health Canada guidance may not be entirely consistent with the ICH document, but the Health Canada-implemented ICH guidance will take precedence in such cases.

The adoption comes nearly two years after ICH finalized the E17 document. European and American regulators adopted the guidelines last year.